The Preston Robert Tisch Brain Tumor Center at Duke

Clinical Trials for Adults | Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects with Recurrent Malignant Glioma


  • To assess the response rate of AMG 102 (C-Met inhibitor) and Avastin (anti-VEGF) treatment in subjects with advanced malignant glioma
  • To estimate overall survival and 6-month progression-free survival rates in this population 
  • To assess the safety in this population

Eligibility, Inclusion

  • Patients must have recurrent histologically confirmed diagnosis of WHO grade IV malignant glioma (glioblastoma multiforme or gliosarcoma) with no more than 3 prior progressions
  • Age ≥ 18 years
  • Karnofsky ≥ 60%
  • At least 4 weeks between either prior tumor biopsy or prior major surgical procedure and study enrollment
  • Measurable disease with no CNS hemorrhage as assessed by MRI or CT scan
  • Lab parameters that meet eligibility criteria – CBC with diff, CMP, UA
  • If sexually active, patients will take contraceptive measures for the duration of treatment

Exclusion Criteria

  • Pregnancy or breast-feeding
  • Baseline ECG with QTc > 0.45 second
  • Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids
  • Thrombosis or vascular ischemic events within the last twelve months, such as deep venous thrombosis, pulmonary embolism, transient ischemic attack, cerebral infarction, or myocardial infarction
  • Active infection requiring IV antibiotics 7 days before enrollment
  • History of central nervous system bleeding as defined by stroke or intraocular bleed (including embolic stroke) within 6 months before enrollment
  • Evidence of acute intracranial hemorrhage; except for subjects with stable grade 1 hemorrhage
  • Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 consecutive scans or histopathologic confirmation
  • Treated previously with any c-Met or HGF targeted therapy
  • Treated previously with VEGF or VEGFR therapies, including antibodies and tyrosine kinase inhibitors
  • Treated with thalidomide or tamoxifen within 1 week before enrollment or has not recovered from the toxic effects of such cancer therapy
  • Treated with immunotherapeutic agents, vaccines, or MAb therapy within 4 weeks before enrollment or have not recovered from the toxic effects of such cancer therapy
  • Treated with alkylating agents within 4 weeks before enrollment or has not recovered from the toxic effects of such cancer therapy
  • Treated with chemotherapy (non-alkylating agents) within 2 weeks before enrollment or has not recovered from the toxic effects of such cancer therapy
  • Plans to receive surgery, radiation therapy or other elective surgeries during the course of the study
  • Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months before enrollment) that could compromise participation in the study
  • Concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except: Use of low dose coumadin-type anticoagulants (≤ 2 mg PO QD) low molecular weight heparins (LMWH), e.g. Enoxaparin sodium (Lovenox) and unfractionated heparin for prophylaxis against central venous catheter thrombosis is allowed
  • Grade 2 or greater peripheral edema or effusion (pleural, pericardial, or ascites)
  • Inability to comply with study and/or follow-up procedure
  • Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study

Avastin-Specific Exclusion Criteria (Subjects meeting any of the following criteria are ineligible for study entry)

  • Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg)
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • New York Heart Association (NYHA) Grade II or greater congestive heart failure
  • History of myocardial infarction or unstable angina within 6 months prior to Day 1, the day protocol therapy starts
  • History of stroke or transient ischemic attack within 6 months prior to Day 1
  • Significant vascular disease (e.g. aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) (within 6 months prior to Day 1)
  • History of hemoptysis ( 1/2 teaspoon of bright red blood per episode) within 28 days prior to Day 1
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1
  • Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
  • Serious, non-healing wound, active ulcer or untreated bone fracture
  • Proteinuria as defined by > +1 on urinalysis dipstick
  • Known hypersensitivity to any component of Avastin

Treatment Plan

  • All treatments at Duke
  • Infusions will be every other week (days 1,15 and 29 of each 42 day of cycle)
  • Amgen 102 is provided free by Amgen
  • Lab work  every other week
  • Return to clinic every 6 weeks and with MRI and ECG
  • May receive treatment until tumor progresses, have too many toxicities, or want to come off study 

Printer Friendly Page Send this Story to a Friend